CompletedInterventionalPhase 1Last updated Jul 26, 2017

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients With B Cell Non-Hodgkin'sLymphoma"

Overview

ClinicalTrials.gov ID: NCT00500058
Lead Sponsor: GlaxoSmithKlineINDUSTRY
Brief Summary: The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL). This study will use a standard treatment regimen of Rituximab in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies.
Study Type

Status

Overall Status: Completed
Start Date: Jul 31, 2007Actual
Primary Completion Date: Mar 4, 2010Actual
Completion Date: Mar 4, 2010Actual

Study Record Dates

First Submitted: Jul 10, 2007
First Submitted that Met QC Criteria: Jul 10, 2007
First Posted: Jul 12, 2007Estimated
Last Update Submitted that Met QC Criteria: Jul 24, 2017
Last Update Posted: Jul 26, 2017Actual
Last Verified: Jul 2017

NCT00347971Completed

Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

NCT00004260Completed

Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

NCT00994643Completed

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

NCT00057447Terminated

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

NCT00100737Terminated

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

NCT00026182Completed

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma